Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Simon D. Gibbs"'
Autor:
Kenneth JC Lim, Cameron Wellard, Dipti Talaulikar, Joanne LC Tan, Joanna Loh, Pratheepan Puvanakumar, James A Kuzich, Michelle Ho, Matthew Murphy, Nicole Zeglinas, Michael SY Low, David Routledge, Andrew BM Lim, Simon D Gibbs, Hang Quach, Sue Morgan, Elizabeth Moore, Slavisa Ninkovic
Publikováno v:
eJHaem, Vol 4, Iss 3, Pp 639-646 (2023)
Abstract The prognostic impact of t(11;14) in multiple myeloma (MM) needs to be better understood to inform future treatment decisions. The Australian Lymphoma Leukaemia Group embarked on a retrospective, observational cohort study using real‐world
Externí odkaz:
https://doaj.org/article/cb1202c0223440efb5b3d9e055739c68
Autor:
Jonathan L. Kaufman, Hang Quach, Rachid C. Baz, Annette Juul Vangsted, Shir-Jing Ho, Simon J Harrison, Torben Plesner, Philippe Moreau, Simon D. Gibbs, Eva Medvedova, Muhammad Jalaluddin, Jeremy A. Ross, Leanne Lash Fleming, Yan Luo, Nizar Jacques Bahlis
Publikováno v:
Blood. 140:7261-7263
Autor:
Murielle Roussel, Peter Mollee, Antoine Huart, Hasib Sidiqi, Noemi Horvath, Lionel Karlin, Caroline Jacquet, Pierre Morel, Cecile Leyronnas, Sebastien Bender, Frank Bridoux, Arnaud Jaccard, Simon D. Gibbs
Publikováno v:
Blood. 140:12618-12620
Autor:
Ashutosh D. Wechalekar, M. Teresa Cibeira, Simon D. Gibbs, Arnaud Jaccard, Shaji Kumar, Giampaolo Merlini, Giovanni Palladini, Vaishali Sanchorawala, Stefan Schönland, Christopher Venner, Mario Boccadoro, Efstathios Kastritis
Publikováno v:
Amyloid. 30:3-17
This guideline has been developed jointly by the European Society of Haematology and International Society of Amyloidosis recommending non-transplant chemotherapy treatment for patients with AL amyloidosis.A review of literature and grading of eviden
Autor:
Peter Mollee, John Reynolds, Wojciech Janowski, Hang Quach, Philip Campbell, Simon D. Gibbs, Sophie Lee, James D'Rozario, Kerry Taylor, Tara Cochrane, Craig Thomas Wallington-Beddoe, Fiona Kwok, Nicholas Weber, Ian H Kerridge, Helen Weston, P. Joy Ho, Noemi Horvath, Flora Yuen, Andrew Spencer
Publikováno v:
Blood. 138:2728-2728
Introduction Daratumumab, when added to standard of care regimens in relapsed and untreated myeloma, has consistently demonstrated significant improvements in response rates, induction of MRD negative responses and prolonged progression-free survival
Autor:
Andrew Lim, David Routledge, Nicole Zeglinas, Michelle Ho, Pratheepan Puvanakumar, Matthew Murphy, Sue Morgan, Kenneth J C Lim, James Anton Kuzich, Michael S.Y. Low, Joanna Loh, Dipti Talaulikar, Joanne L. C. Tan, Slavisa Ninkovic, Simon D. Gibbs
Publikováno v:
Blood. 138:4752-4752
Introduction/ Background Traditionally, MM harbouring t(11;14) is considered standard risk disease. In the era of novel therapies, however, pts with t(11;14) are reported to have inferior outcomes to other standard risk pts. Evidence of response to t